IDEXX Laboratories, Inc. (IDXX)

Market Cap	50.25B +44.7%
Revenue (ttm)	4.30B +10.4%
Net Income	1.06B +19.3%
EPS	13.08 +22.6%
Shares Out	79.85M
PE Ratio	48.12
Forward PE	43.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	537,917
Open	616.77
Previous Close	617.20
Day's Range	606.04 - 636.05
52-Week Range	356.14 - 769.98
Beta	1.66
Analysts	Buy
Price Target	715.00 (+13.61%)
Earnings Date	Feb 2, 2026

About IDXX

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 21, 1991
• Employees: 11,000
• Stock Exchange: NASDAQ
• Ticker Symbol: IDXX
• Website: https://www.idexx.com

Financial Performance

In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.

Analyst Summary

According to 9 analysts, the average rating for IDXX stock is "Buy." The 12-month stock price target is $715.0, which is an increase of 13.61% from the latest price.

Price Target

$715.0

(13.61% upside)

Analyst Consensus: Buy